References
- 1. Al Ajlouni M, Abujbara M, Batieha A, et al. Prevalence of lipohypertrophy and associated risk factors in insulin-treated patients with type 2 diabetes mellitus. Int J Endocrinol Metab. 2015; 13(2): e20776.10.5812/ijem.20776439794725926852
- 2. American Diabetes Association. Standards of Medical Care in Diabetes – 2019. Diabetes Care. 2019; 42 (1): 1-204.
- 3. Ariza-Andraca CR, Altamirano-Bustamante E, Frati-Munari AC, et al. Delayed insulin absorption due to subcutaneous edema. Arch Invest Med. 1991; 22: 229-233.
- 4. Barola A, Tiwari P, Bhansali A, et al. Insulin-Related Lipohypertrophy: Lipogenic Action or Tissue Trauma? Front Endocrinol (Lausanne). 2018; 9: 638.
- 5. Blanco M, Hernandez MT, Strauss KW, et al. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013; 39(5): 445-453.10.1016/j.diabet.2013.05.00623886784
- 6. Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. Brit Med J. 2003; 327: 383-384.10.1136/bmj.327.7411.383112679512919996
- 7. Frid A, Linden B. Computed tomography of injection sites in patients with diabetes mellitus. Injection and Absorption of Insulin. Stockholm: Thesis, 1992.
- 8. Frid AH, Kreugel G, Grassi G, et al. New Insulin Delivery Recommendations 2016 Mayo Foundation for Medical Education and Research. Mayo Clin Proc. 2016; 91(9): 1231-1255.10.1016/j.mayocp.2016.06.01027594187
- 9. Gupta SS, Gupta KS, Gathe SS, et al. Clinical Implications of Lipohypertrophy Among People with Type 1 Diabetes in India. Diabetes Technol Ther. 2018; 20(7): 483-491. 10. Hambridge K. The management of lipohypertrophy in diabetes care. Br. J. Nurs. 2007; 16: 520-524.
- 11. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp. Clin. Endocrinol. Diabetes. 1996; 104: 106-110.
- 12. Hayek AA, Robert AA, Braham RB, et al. Frequency of lipohypertrophy and associated risk factors in young patients with type 1 diabetes: a cross-sectional study. Diabetes Ther. 2016; 7(2): 259–267.10.1007/s13300-016-0161-3490097126979975
- 13. Hernar I, Haltbakk J, Broström A. Diff erences in depression, treatment satisfaction and injection behavior in adults with type 1 diabetes and diff erent degrees of lipohypertrophy. J Clin Nurs. 2017; 26(23-24): 4583–4596.10.1111/jocn.1380128295770
- 14. Ji L, Sun Z, Li Q, et al. Lipohypertrophy in China: Prevalence, Risk Factors, Insulin Consumption, and Clinical Impact. Diabetes Technol Ther. 2017; 19(1): 61-67.10.1089/dia.2016.033428099050
- 15. Johansson U, Amsberg S, Hannerz L, et al. Impaired Absorption of insulin Aspart from Lipohypertrophic Injection Sites. Diabetes Care. 2005; 28: 2025-2027.10.2337/diacare.28.8.202516043749
- 16. LaRosa C, Makkar H, Grant-Kels JM. Approach to the total body skin examination in adults and children: Kids are not just little people. Clinics in Dermatology. 2017; 35(6): 500-503.10.1016/j.clindermatol.2017.08.00129191341
- 17. Manash P, Baruah MP, Sanjay K, et al. An Audit of Insulin Usage and Insulin Injection Practices in a Large Indian Cohort. Indian J Endocrinol Metab. 2017; 21(3): 443–452.10.4103/ijem.IJEM_548_16543473128553603
- 18. Nagase T, Iwaya K, Iwaki Y, et al. Insulin-derived Amyloidosis and Poor Glycemic Control. A Case Series The American Journal of Medicine. 2014; 127: 450–454.
- 19. Olmo DZ, Vlacho B, Fernández J, et al. Safety of the reuse of needles for subcutaneous insulin injection: A systematic review and meta-analysis. Int J Nurs Stud. 2016; 60: 121-132.10.1016/j.ijnurstu.2016.04.01027297374
- 20. Overland J, Molyneaux L, Tewari S, et al. Lipohypertrophy, Does it matter in daily life? A study using a continuous glucose monitoring system. Diab, Obes Metab. 2009; 11: 460-463.10.1111/j.1463-1326.2008.00972.x19236441
- 21. Polinski JM, Kim SC, Jiang D, et al. Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: Understanding the challenges associated with progression of therapy (MOSAIc) BMC. Endocr Disord. 2015; 15: 46.10.1186/s12902-015-0044-z456384526353820
- 22. Polish Diabetes Association. Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clinical Diabetology. 2019; 8(1): 1-103.10.5603/DK.2018.0001
- 23. Rozporządzenie Ministra Zdrowia z dnia 28 lutego 2017 r. w sprawie rodzaju i zakresu świadczeń zapobiegawczych, diagnostycznych, leczniczych i rehabilitacyjnych udzielanych przez pielęgniarkę albo położną samodzielnie bez zlecenia lekarskiego (Dz.U. 2017 poz. 497).
- 24. Saez-de Ibarra L, Gallego F. Factors related to lipohypertrophy in insulin-treated diabetic patients; role of educational intervention. Pract Diab Int. 1998; 15: 9-11.10.1002/pdi.1960150108
- 25. Vardar B, Kızılcı S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007; 77(2): 231–236.10.1016/j.diabres.2006.12.02317303282
- 26. Young RJ, Hannan WJ, Frier BM, et al. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care. 1984; 7: 479-480.10.2337/diacare.7.5.4796389062